Feasibility Study of the Assessment of Symptom-Related Cytokines in AML/MDS Patients Undergoing Allogeneic Blood or Marrow Transplantation
Principal Investigator: Xin Shelley Wang, M.D., M.P.H.
Multiple studies of the posttransplantation period have found that many patients continue to experience distressing physical symptoms such as fatigue, weakness, nausea and vomiting, diarrhea or constipation, dyspnea, sleep disturbance, anorexia, mouth sores, skin disorders and sexual dysfunction. Longitudinal studies are needed to provide a comprehensive assessment of the frequency, severity and interrelationships of symptoms that patients experience.
- To assess the self-reported symptoms and the plasma cytokine levels of AML/MDS patients pretransplantation and posttransplantation with allogeneic blood and marrow in order to identify changes in symptoms (or symptom clusters) and changes in cytokines that may be related to the conditioning regimen and/or to the development of GVHD during the 100 days posttransplant
Screening and enrollment will occur in the outpatient allogeneic transplantation clinic prior to the patient’s admission to the hospital for the pretransplant conditioning regimen and transplant. The MDASI-IVR will be regularly administered to patients via the IVR system during the first 100 days following transplantation. These symptom data will be supplemented with additional symptom measures of mood, pain and fatigue. Quality of life and functional status will also be determined.
The measures include the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT), the MD Anderson Symptom Inventory (MDASI), the Profile of Mood States (POMS) and serum cytokine analysis.
For more information
Contact Lori Williams, R.N., D.S.N., at email@example.com